Showing 8331-8340 of 9739 results for "".
- ChloraDerm Launches Pediatric Offeringhttps://practicaldermatology.com/news/chloraderm-launches-pediatric-offering/2458683/entrotech life sciences (ELS) announced the availability of FDA-Cleared ChloraDerm in a new 1.75"x 1.75" configuration, ideal for pediatric patient use. ChloraDerm is the only transparent film dressing containing the Chlorhexidine Advantage, a safe, colophony-and acid-free, edge-t
- Galderma Mans Up with New Cetaphil Line for Menhttps://practicaldermatology.com/news/cetaphils-newest-line-targets-men/2458690/Galderma Laboratories, L.P is manning up with the launch of a new skin care line for men. The Cetaphil® Men line comprises Cetaphil® Men Daily Face Wash, Cetaphil® M
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their c
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o
- Hilary Baldwin, MD, Named Medical Director of ATRChttps://practicaldermatology.com/news/hilary-baldwin-md-named-medical-director-of-atrc/2458710/The newly opened Acne Treatment and Research Center (ATRC) in Morristown, NJ, has tapped Hilary Baldwin, MD, to serve as its medical director. Dr. Baldwin received her BA and MA in biology from Boston Uni
- ASDS: Cosmetic Treatments Can Correct Facial Deformities Toohttps://practicaldermatology.com/news/asds-cosmetic-treatments-can-correct-facial-deformities-too/2458714/Soft-tissue fillers, neurotoxins and lasers can be used to correct facial deformities caused by a variety of medical conditions, according to information presented at the 2015 American Society for Dermatologic Surgery meeting. During the session, Wa
- Valeant: FDA Accepts BLA for Brodalumabhttps://practicaldermatology.com/news/valeant-fda-accepts-bla-for-brodalumab/2458726/The FDA has accepted for review the Biologics License Application (BLA) submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, 210mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. The FDA has a
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<